In addition, increased Wnt5a expression levels in melanoma tissues as well as diminished levels of the soluble Wnt antagonist, Dkk-1, have been associated with an inferior clinical outcome in patients with advanced melanoma (59–63). This evidence concerns the gene DKK1 and melanoma.